Metformin Plus Tyrosine Kinase Inhibitors in Epidermal Growth Factor Receptor-Mutated Non-Small Cell Lung Cancer-Reply

Affiliations

Comment

Oscar Arrieta et al. JAMA Oncol. 2020.

. 2020 May 1;6(5):782-783.

doi: 10.1001/jamaoncol.2020.0062.

¹ Thoracic Oncology Unit, Instituto Nacional de Cancerología (INCan), México City, México.

No abstract available

Comment on

Effect of Metformin Plus Tyrosine Kinase Inhibitors Compared With Tyrosine Kinase Inhibitors Alone in Patients With Epidermal Growth Factor Receptor-Mutated Lung Adenocarcinoma: A Phase 2 Randomized Clinical Trial.
Arrieta O, Barrón F, Padilla MS, Avilés-Salas A, Ramírez-Tirado LA, Arguelles Jiménez MJ, Vergara E, Zatarain-Barrón ZL, Hernández-Pedro N, Cardona AF, Cruz-Rico G, Barrios-Bernal P, Yamamoto Ramos M, Rosell R. Arrieta O, et al. JAMA Oncol. 2019 Nov 1;5(11):e192553. doi: 10.1001/jamaoncol.2019.2553. Epub 2019 Nov 14. JAMA Oncol. 2019. PMID: 31486833 Free PMC article.
Metformin Plus Tyrosine Kinase Inhibitors in Epidermal Growth Factor Receptor-Mutated Non-Small Cell Lung Cancer.
Gao C, Cai S, He Y. Gao C, et al. JAMA Oncol. 2020 May 1;6(5):782. doi: 10.1001/jamaoncol.2020.0059. JAMA Oncol. 2020. PMID: 32163098 No abstract available.